Compare Repligen Corporation Common Stock (RGEN) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs ABRDN Physical Gold Shares ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while ABRDN Physical Gold Shares ETF trades at $39.57 (market cap $7.18B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| RGEN | SGOL | |
|---|---|---|
Market Cap | $11.14B | $7.18B |
Volume | 1,259,263 | 2,482,796 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $194.57 | $51.41 |
52-Week Low | $102.87 | $37.54 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SGOL trades at $39.63, down 0.13% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX showing sell signals. Support levels cluster around $39-40, while resistance is firm at $40. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices pressured by rising rates but supported by geopolitical tensions and strong Chinese imports.
The outlook remains cautious amid interest rate uncertainty, with potential for rebound if yields stabilize or conflict escalates. Risks include persistent inflation driving higher rates, while institutional analysts see mixed paths—some targeting $4,100 by year-end but others $5,000 by mid-2027. Investor sentiment is neutral to bearish short-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
